

Press Release  
Herantis Pharma Plc  
8 February 2021 at 05:20 p.m. EET

## **Herantis Pharma to Participate in the Upcoming Swiss Nordic Bio Conference**

**Herantis Pharma Plc (“Herantis”)**, an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that Craig Cook, Chief Executive Officer, will hold a company presentation in the upcoming Swiss Nordic Bio Conference investor conference, this year taking place virtually.

Event Details:  
Swiss Nordic Bio Conference  
10 – 11 February 2021

On 11 February 2021 all presentations will be available via a digital library, which is accessible to event participants only. Please contact the organizers at the Swiss Nordic Bio Conference if you wish to attend.

**For more information, please contact:**

Julie Silber/Gabriela Urquilla  
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19  
Email: [ir@herantis.com](mailto:ir@herantis.com)

**Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400**  
**Company website: [www.herantis.com](http://www.herantis.com)**

### **About Herantis Pharma Plc**

Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases. These include i. CDFN biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. For more information, please visit <https://www.herantis.com>